A5062839002- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Boron Compounds in Chemistry
- Renal and related cancers
- Nicotinic Acetylcholine Receptors Study
- Nanomaterials for catalytic reactions
- Memory and Neural Mechanisms
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Pharmacological Effects and Toxicity Studies
- Diet and metabolism studies
- Semiconductor materials and devices
- Brain Metastases and Treatment
- Nanoparticle-Based Drug Delivery
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- MXene and MAX Phase Materials
- Ovarian cancer diagnosis and treatment
- Click Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Cancer Diagnosis and Treatment
- Ion channel regulation and function
- Microtubule and mitosis dynamics
- Attention Deficit Hyperactivity Disorder
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
Bionomics (Australia)
2012-2025
Baylor University Medical Center
2015
McKesson (United States)
2012
Nebraska Cancer Specialists
2012
Texas Oncology
2012
New Mexico Cancer Center
2012
Indiana University Health
2012
Indiana University – Purdue University Indianapolis
2012
UNM Comprehensive Cancer Center
2012
Abstract Drugs that are clinically effective against anxiety disorders modulate the innate defensive behaviour of rodents, suggesting these illnesses reflect altered functioning in brain systems process threat. This hypothesis is supported humans by discovery intensity threat-avoidance benzodiazepine anxiolytic lorazepam. However, studies used healthy human participants, raising questions as to their validity disorder patients, well generalisability beyond GABAergic drugs. BNC210 a novel...
BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy safety of the combination were explored in patients metastatic renal cell carcinoma (mRCC).
BackgroundGeneralized anxiety disorder is associated with hyperactivity in the amygdala-prefrontal networks, and normalization of this aberrant function thought to be critical for successful treatment. Preclinical evidence implicates cholinergic neurotransmission these systems suggests that modulation may have anxiolytic effects. However, effects modulators on anxiety-related networks humans not been investigated.MethodsWe administered a novel α7 nicotinic acetylcholine receptor–negative...
Post-traumatic stress disorder (PTSD) is a serious, debilitating, and prevalent psychiatric condition occurring in people who are traumatized experience intense, disturbing thoughts feelings that persist. BNC210 novel α7 nicotinic acetylcholine receptor-negative allosteric modulator developed to treat PTSD.
373 Background: BNC105P is a Vascular Disruption Agent (VDA) that destabilizes tubulin polymers leading to selective damage of tumor vasculature, hypoxia and associated necrosis. also has direct anti-proliferative action on cancer cells. Up regulation the mTOR pathway been identified as survival response by hypoxic insult. Preclinical investigations demonstrated effective at selectively damaging vasculature in primary metastatic lesions. Furthermore, monotherapy compared well with sunitinib...
Abstract BNC105 is a tubulin depolymerisation agent. Its activity includes effects on both cancer cells and solid tumor microvasculature. shows evidence of strong anti-cancer efficacy in vitro animal models. In tumors its driven by selective destruction vasculature (Vascular Disrupting Agent - VDA) direct action through suppression their proliferation. non-proliferating blood cancers (e.g. Chronic Lymphocytic Leukaemia) activates pro-apoptotic proteins, which mediate cell death. BNC105P may...
5524^ Background: BNC105P is a tubulin polymerization inhibitor and vascular disrupting agent (VDA) selectively active against tumor endothelium. Pre-clinical data has demonstrated greater than additive activity of when combined with platinum or gemcitabine. The primary objective this study was to evaluate the safety tolerability in combination gemcitabine carboplatin patients recurrent ovarian cancer, find dose suitable for evaluation randomized trial. Methods: Patients cancer who...
TPS194 Background: Treatment options remain limited in progressive metastatic renal cell carcinoma (mRCC) for patients who are refractory to tyrosine kinase inhibitors (TKI). with everolimus following previous sunitinib and/or sorafenib has been associated a significant improvement PFS compared placebo (4.9 vs 1.9 months; Kay et al. ASCO Abs No. 278, 2009). A potential enhancement efficacy may result from the combination of this mTOR-targeting agent and Vascular Disruption Agent (VDA). VDAs...
4563 Background: BNC105P is an inhibitor of tubulin polymerization. In vivo exposure to leads selective damage tumor vasculature in both primary and metastatic lesions, causing disruption blood flow tumors, hypoxia associated necrosis. also has a direct anti-proliferative action on cancer cells. Up regulation the mTOR pathway been identified as cellular response hypoxic stress. The combined use with agent active against may improve clinical outcome patients progressive mRCC who are...
Event Abstract Back to Modulation of Anxiety-Relevant Neural Circuits in Generalized Anxiety Disorder: A Novel Cholinergic System Pharmacotherapy Approach. Fiona Patrick1*, Toby Wise1, 2, Nicholas Meyer3, Ndaba Mazibuko4, Alice Oates5, Anne M. Van Der Bijl6, Philippe Danjou7, Susan O'Connor8, Elizabeth Doolin9, Caroline Wooldridge4, Christine Macare1, Steven C. Williams2, 4, 5, Adam Perkins1 and Allan H. Young1 1 Institute Psychiatry, Psychology & Neuroscience (IoPPN), Psychological...
475 Background: The vascular disrupting agent (VDA) BNC105P shows synergy with everolimus in preclinical models. DisrupTOR-1 trial included a phase I component exploring this combination and randomized II comparing (Arm A) to monotherapy B) (Pal et al. ESMO 2014). Methods: Pts clear cell mRCC 1-2 prior therapies (including ≥1 VEGF-TKI) were the study component. In Arm A, patients received 7 day lead-in dose of followed by dosing BNC105P. Patients A had optional blood collections...
<p>Supplementary Figure 1. PFS in patients receiving BNC105P monotherapy after crossover.</p>
<p>Supplementary Figure 2. CONSORT diagram reflecting patients that received monotherapy with BNC105P after progression on everolimus monotherapy.</p>
<p>Supplementary Figure 2. CONSORT diagram reflecting patients that received monotherapy with BNC105P after progression on everolimus monotherapy.</p>
<p>Supplementary Figure 1. PFS in patients receiving BNC105P monotherapy after crossover.</p>